Sort by 'comments'
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended for use as a first choice for patients with multiple myeloma whose disease is refractory to at…
Current Trends in the Management of Advanced and Late Stage Prostate Cancer with Dr. Maha Hussain
When should patients start asking about involving an oncologist in their care, how can we manage quality of life issues while being treated for advanced, metastatic, and castration-resistant prostate cancer? We are discussing how to manage advanced and late stage…
Becoming a part of the solution: The Metastatic Prostate Cancer Project
The Broad Institute in Cambridge, Massachusetts, is one of the most sophisticated bioscience and biotechnology research centers in North America. It seeks to empower a revolution in biomedicine that will accelerate the speed at which we can conquer disease. The…
Latest in Brain Tumor Treatments and Trials
Brain tumors can be among the most challenging cancers to treat. The blood-brain barrier, a natural defense mechanism that shields the brain from harm can also prevent cancer treatments from reaching tumors. However, immunotherapy, precision medicine, and the other new…
Covid-19 Vaccines – What Multiple Myeloma Patients Should Know?
Multiple myeloma patients are often immunosuppressed for months following treatments such as maintenance therapies, immunosuppressive drugs, hematopoietic cell transplant (HCT) and CAR-T therapies. They are at higher risk for serious complications from the SARS-CoV-2 virus leading to hospitalizations and ICU…